Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RISPERIDONE | 0.25MG | TABLET | Resolved | 2017-08-23 | 2017-11-29 | 20122 |
| APO-RISPERIDONE | 0.25MG | TABLET | Resolved | 2017-08-31 | 2017-11-30 | 20707 |
| APO-RISPERIDONE | 4.0MG | TABLET | Resolved | 2024-12-19 | 2025-02-21 | 246062 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2025-01-30 | 2025-02-21 | 249089 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2024-09-27 | 2025-02-21 | 238841 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2024-10-10 | 2025-02-14 | 239819 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2024-10-18 | 2025-02-14 | 240627 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2024-10-24 | 2025-02-21 | 241072 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2024-11-07 | 2025-02-21 | 242214 |
| APO-RISPERIDONE | 0.25MG | TABLET | Resolved | 2023-07-13 | 2023-08-18 | 198480 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2023-07-13 | 2023-08-04 | 198486 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2023-07-13 | 2023-08-04 | 198489 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2023-09-22 | 2023-12-01 | 205002 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2023-11-10 | 2024-04-26 | 209957 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2022-07-05 | 2022-10-31 | 164083 |
| APO-RISPERIDONE | 0.25MG | TABLET | Resolved | 2022-07-29 | 2022-10-31 | 165674 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2022-07-29 | 2022-12-17 | 165677 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2023-05-19 | 2023-08-04 | 192803 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2023-05-19 | 2023-08-04 | 192821 |
| APO-RISPERIDONE | 1MG | SOLUTION | Resolved | 2018-03-27 | 2018-05-15 | 44114 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |